Carbon monoxide alleviates ethanol-induced oxidative damage and inflammatory stress through activating p38 MAPK pathway

Toxicol Appl Pharmacol. 2013 Nov 15;273(1):53-8. doi: 10.1016/j.taap.2013.08.019. Epub 2013 Aug 28.

Abstract

Stress-inducible protein heme oxygenase-1(HO-1) is well-appreciative to counteract oxidative damage and inflammatory stress involving the pathogenesis of alcoholic liver diseases (ALD). The potential role and signaling pathways of HO-1 metabolite carbon monoxide (CO), however, still remained unclear. To explore the precise mechanisms, ethanol-dosed adult male Balb/c mice (5.0g/kg.bw.) or ethanol-incubated primary rat hepatocytes (100mmol/L) were pretreated by tricarbonyldichlororuthenium (II) dimmer (CORM-2, 8mg/kg for mice or 20μmol/L for hepatocytes), as well as other pharmacological reagents. Our data showed that CO released from HO-1 induction by quercetin prevented ethanol-derived oxidative injury, which was abolished by CO scavenger hemoglobin. The protection was mimicked by CORM-2 with the attenuation of GSH depletion, SOD inactivation, MDA overproduction, and the leakage of AST, ALT or LDH in serum and culture medium induced by ethanol. Moreover, CORM-2 injection or incubation stimulated p38 phosphorylation and suppressed abnormal Tnfa and IL-6, accompanying the alleviation of redox imbalance induced by ethanol and aggravated by inflammatory factors. The protective role of CORM-2 was abolished by SB203580 (p38 inhibitor) but not by PD98059 (ERK inhibitor) or SP600125 (JNK inhibitor). Thus, HO-1 released CO prevented ethanol-elicited hepatic oxidative damage and inflammatory stress through activating p38 MAPK pathway, suggesting a potential therapeutic role of gaseous signal molecule on ALD induced by naturally occurring phytochemicals.

Keywords: ALT; AST; Alcohol; CO; CORM-2; Carbon monoxide; GSH; HO-1; Inflammation; LDH; MDA; Oxidative damage; SOD; alanine aminotransferases; aspartate aminotransferases; carbon monoxide; heme oxygenase-1; lactate dehydrogenase; malondialdehyde; p38 MAPK; reduced glutathione; superoxide dismutase; tricarbonyldichlororuthenium (II) dimmer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Anthracenes / pharmacology
  • Aspartate Aminotransferases / blood
  • Carbon Monoxide / pharmacology*
  • Ethanol / adverse effects*
  • Flavonoids / pharmacology
  • Glutathione / metabolism
  • Heme Oxygenase-1 / metabolism
  • Hepatocytes / drug effects
  • Imidazoles / pharmacology
  • Interleukin-6 / antagonists & inhibitors
  • Interleukin-6 / blood
  • L-Lactate Dehydrogenase / blood
  • Liver Diseases, Alcoholic / etiology
  • Liver Diseases, Alcoholic / pathology
  • Liver Diseases, Alcoholic / prevention & control
  • MAP Kinase Signaling System*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Organometallic Compounds / pharmacology
  • Oxidative Stress / drug effects*
  • Phosphorylation
  • Phytochemicals
  • Pyridines / pharmacology
  • Quercetin / pharmacology
  • Rats
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / blood
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Anthracenes
  • Flavonoids
  • Imidazoles
  • Interleukin-6
  • Organometallic Compounds
  • Phytochemicals
  • Pyridines
  • Tumor Necrosis Factor-alpha
  • tricarbonyldichlororuthenium (II) dimer
  • pyrazolanthrone
  • Ethanol
  • Carbon Monoxide
  • Quercetin
  • L-Lactate Dehydrogenase
  • Heme Oxygenase-1
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • p38 Mitogen-Activated Protein Kinases
  • Glutathione
  • SB 203580
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one